Megan H. Noe

Megan H. Noe

Auto-generated profile, based on publicly available information

Megan H. Noe

Department of Dermatology, Brigham and Women’s Hospital, Boston, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
MNMegan H. Noe
Megan H. Noe
MRMisha Rosenbach
Misha Rosenbach
RHRebecca A. Hubbard
Rebecca A. Hubbard
AMArash Mostaghimi
Arash Mostaghimi
ACAdela R. Cardones
Adela R. Cardones
RMRobert G. Micheletti
Robert G. Micheletti
Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) is a spectrum of rare, severe mucocutaneous drug reaction associated with significant morbidity and mortality. Clinically, patients present with atypical targetoid lesions or generalized erythema progressing to full-thickness epidermal necrosis. Patients are classified by the extent of epidermal detachment, with SJS representing less than 10% body surface area (BSA); SJS/TEN overlap, 10% to 30% BSA; and TEN, greater than 30% BSA. In-hospital mortality in adults has been estimated to be between 12% and 40% based on the extent of epidermal detachment at presentation.1,2 A recent study in the United States, based on diagnosis codes from the Nationwide Inpatient Sample, reported mortality rates of 4.8% for SJS, 19.4% for SJS/TEN overlap, and 14.8% for TEN.3 Unfortunately, the rarity of the disease makes it difficult to collect generalizable information to understand patient prognosis.

1 April 2018 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
AOAlexis Ogdie
Alexis Ogdie
SGSungat K. Grewal
Sungat K. Grewal
MNMegan H. Noe
Megan H. Noe
DSDaniel B. Shin
Daniel B. Shin
JTJunko Takeshita
Junko Takeshita
JGJoel M. Gelfand
Joel M. Gelfand

1 January 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
JGJoel M. Gelfand
Joel M. Gelfand
DSDaniel B. Shin
Daniel B. Shin
Abass AlaviAbass Alavi
Abass Alavi
DTDrew Torigian
Drew Torigian
TWThomas J. Werner
Thomas J. Werner
NMNehal N. Mehta
Nehal N. Mehta

1 January 2018 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
MNMegan H. Noe
Megan H. Noe
DSDaniel B. Shin
Daniel B. Shin
MWMarilyn T. Wan
Marilyn T. Wan
JGJoel M. Gelfand
Joel M. Gelfand

1 September 2017 in Current Opinion in Pulmonary Medicine
Verified
Journal Article
Closed access
PDF file
MNMegan H. Noe
Megan H. Noe
MRMisha Rosenbach
Misha Rosenbach
Cutaneous sarcoidosis occurs in up to 30% of patients with sarcoidosis and skin findings are often the initial presenting symptom. Cutaneous sarcoidosis is a rare skin disease and many aspects of the disease presentation and treatment are not well understood. This review will highlight developments in the epidemiology, clinical presentation, diagnosis and treatment of cutaneous sarcoidosis over the past several years. Epidemiological studies from several different populations reaffirm that cutaneous sarcoidosis is more common in women and is often the presenting symptom of systemic sarcoidosis. Recently, more cases are being reported in association with oncologic immune modulators, which will be of great interest as use of those agents increases. Also, ultrasound has shown promise for the imaging of cutaneous granulomas for disease assessment and measuring response to treatment. Finally, the treatment of cutaneous sarcoidosis remains difficult and is based largely on retrospective data with a paucity of large, prospective trials. There have been recently introduced and validated cutaneous scoring tools which show promise and may lead to more high-quality studies going forward. The recent developments in cutaneous sarcoidosis have identified many new pharmacologic and physical triggers of disease, but the evidence for effective treatment is still lacking. Further research is necessary to improve the care of patients with cutaneous sarcoidosis.

8 December 2021 in JAMA Dermatology
Verified
Journal Article
Closed access
PDF file
MNMegan H. Noe
Megan H. Noe
MWMarilyn T. Wan
Marilyn T. Wan
AMArash Mostaghimi
Arash Mostaghimi
JGJoel M. Gelfand
Joel M. Gelfand
PGPustular Psoriasis in the US Research Group
Pustular Psoriasis in the US Research Group
AYAlexander Yang
Alexander Yang
Importance Generalized pustular psoriasis (GPP) is a chronic, orphan disease with limited epidemiological data. Objective To describe the clinical characteristics, treatments, longitudinal disease course, and disease-specific health care utilization among patients with GPP across the United States. Design, Setting, and Participants A retrospective longitudinal case series involving 95 adults who met the European Rare and Severe Psoriasis Expert Network consensus definition for GPP and were treated at 20 US academic dermatology practices between January 1, 2007, and December 31, 2018. Main Outcomes and Measures The primary outcome is to describe the patient characteristics, associated medical comorbidities, treatment patterns complications, and GPP–specific health care utilization. Results Sixty-seven of 95 patients (70.5%) were women (mean age, 50.3 years [SD, 16.1 years]). In the initial encounter, 35 patients (36.8%) were hospitalized and 64 (67.4%) were treated with systemic therapies. In total, more than 20 different systemic therapies were tried. During the follow-up period, 19 patients (35.8%) reported hospitalizations at a median rate of 0.5 hospitalizations per year (IQR, 0.4-1.6). Women had a decreased risk of an emergency department or hospital encounter (odds ratio, 0.19; 95% CI, 0.04-0.83). Conclusions and Relevance Generalized pustular psoriasis is a rare, chronic disease without standard treatment and is associated with continued health care utilization over time.